Craig M. Crews

The company gained significant attention in November 2025 when Johnson & Johnson announced its acquisition of Halda Therapeutics in a multi-billion dollar transaction. Multiple financial and pharmaceutical news sources reported the deal valued at approximately $3 billion, characterizing it as a major strategic move in the biotech sector.

This acquisition represents one of the substantial investments in targeted protein degradation platforms, reflecting growing pharmaceutical industry confidence in this therapeutic approach. The deal highlights continued commercial interest in biotechnology companies developing novel cancer treatments that address previously undruggable targets through innovative mechanisms.